Stock Events

Stock Events

Allergy Therapeutics 

$0.11
8
+$0+0% Tuesday 20:00

Statistics

Day High
0.11
Day Low
0.11
52W High
0.11
52W Low
0.08
Volume
15,000
Avg. Volume
0
Mkt Cap
524.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q4 2023
Q1 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
-0.59
-0.39
-0.2
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-74.04%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
147.04MRevenue
-108.87MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGYTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alaska Air Group
ALK
Mkt Cap4.81B
ALK-Abelló is a leading company in the field of allergy immunotherapy, directly competing with Allergy Therapeutics in developing treatments for allergic conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, through its development of Dupixent for various allergic conditions, competes in the allergy treatment market, impacting companies like Allergy Therapeutics.
Sanofi
SNY
Mkt Cap124.45B
Sanofi, in partnership with Regeneron, markets Dupixent, a direct competitor in the allergy treatment space, affecting Allergy Therapeutics' market share.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines that could prevent allergic reactions, indirectly competing with Allergy Therapeutics' approach to allergy management.
Merck
MRK
Mkt Cap214.76B
Merck & Co., with its range of allergy and asthma treatments, competes in the broader market for allergic condition management, impacting Allergy Therapeutics.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca offers several products for respiratory and allergic conditions, competing in the same therapeutic area as Allergy Therapeutics.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline produces a variety of medications for asthma and allergic rhinitis, competing with Allergy Therapeutics in the respiratory and allergy medication market.

About

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Show more...
CEO
Mr. Manuel Llobet
Employees
612
Country
GB
ISIN
GB00B02LCQ05

Listings

F
DE
HHU.F
LSE
GB
AGY.LSE
OTC Link
US
AGYTF

0 Comments

Share your thoughts

FAQ

What is Allergy Therapeutics stock price today?▼
The current price of AGYTF is $0.11 USD — it has increased by +0% in the past 24 hours. Watch Allergy Therapeutics stock price performance more closely on the chart.
What is Allergy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Allergy Therapeutics stocks are traded under the ticker AGYTF.
What is Allergy Therapeutics market cap?▼
Today Allergy Therapeutics has the market capitalization of 524.31M
When is the next Allergy Therapeutics earnings date?▼
Allergy Therapeutics is going to release the next earnings report on September 30, 2026.
What is Allergy Therapeutics revenue for the last year?▼
Allergy Therapeutics revenue for the last year amounts to 147.04M USD.
What is Allergy Therapeutics net income for the last year?▼
AGYTF net income for the last year is -108.87M USD.
How many employees does Allergy Therapeutics have?▼
As of April 04, 2026, the company has 612 employees.
In which sector is Allergy Therapeutics located?▼
Allergy Therapeutics operates in the Health Care sector.
When did Allergy Therapeutics complete a stock split?▼
Allergy Therapeutics has not had any recent stock splits.
Where is Allergy Therapeutics headquartered?▼
Allergy Therapeutics is headquartered in Worthing, GB.